Faeth Therapeutics, Inc.
FTHAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 15, 2026 | Guggenheim | Brad Canino | $70.00(+98%) | $35.37 | TheFly |
| Sep 14, 2026 | UBS | $59.00(+50%) | $39.24 | TheFly | |
| Aug 21, 2026 | Needham | Gil Blum | $56.00(+74%) | $32.10 | TheFly |
| Jul 31, 2026 | Raymond James | Sean McCutcheon | $56.00(+94%) | $28.82 | StreetInsider |
| Jul 27, 2026 | Oppenheimer | $60.00(+105%) | $29.24 | TheFly | |
| Jun 25, 2026 | Robert W. Baird | Jack Allen | $57.00(+131%) | $24.67 | TheFly |
| Jun 22, 2026 | H.C. Wainwright | $60.00(+237%) | $17.82 | TheFly | |
| May 28, 2026 | Loop Capital Markets | Christopher Liu | $50.00(+200%) | $16.65 | StreetInsider |
| May 13, 2024 | Stephens | Sudan Loganathan | $5.00(+218%) | $1.57 | TheFly |
| Dec 13, 2022 | Citigroup | $6.00(+245%) | $1.74 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Nov 4, 2026 |
| BTIG | maintain | Buy | Oct 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2026 |
| BTIG | maintain | Buy | Jul 16, 2026 |
| BTIG | maintain | Buy | Jun 15, 2026 |
| Citigroup | maintain | Buy | Dec 13, 2022 |
| Oppenheimer | maintain | Outperform | Mar 1, 2021 |
| Piper Sandler | maintain | Overweight | Mar 1, 2021 |
Earnings History
Next report: Mar 29, 2027 · EPS est. $-0.70| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $-0.79 | $-0.78 | — | — |
| Aug 4, 2026 | $-2.84 | $-2.64 | — | — |
| May 15, 2026 | $-131.45 | $-0.62 | — | — |
| Mar 30, 2026 | $-3.74 | $-4.81 | — | — |
| Nov 14, 2025 | $-3.62 | $-4.11 | -$4.9M | — |
| Aug 5, 2025 | $-3.91 | $-6.20 | — | — |
| May 6, 2025 | $-5.40 | $-4.20 | — | — |
| Mar 28, 2025 | $-5.40 | $-5.40 | — | — |
News
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, click here. The event will feature key opinion leader and PIK-201 principal investigator David Star.
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 68,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective November 4, 2026 pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment w…
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones. “Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2 PIK-201 trial and received Fast Track designation for PIKT.
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced the appointment of Adam Schayowitz, Ph.D., MBA, to its Board of Directors. Dr. Schayowitz is Executive Vice President and Head of Research and Development at Zymeworks (Nasdaq: ZYME). Dr. Schayowitz has nearly 20 years of experience in oncology drug development and has led dozens of global deve.
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced presentation of preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, in a poster entitled “Characterising the efficacy of multi-node PI3K/AKT/mTOR pathway inhibition with serabelisib and sapanisertib (PIKTOR) in combination with SERDs and a CDK4/6.
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 17,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective October 19, 2026 pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment.
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will present preclinical data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.The poster will be presented on Friday, October 23, and will showcase preclinical data intended to inform the ongoing development of PIKTOR in the FTH-PIK-101 Phase 1b/2 trial…
Sensei Biotherapeutics, Inc. (NASDAQ: FTH - Get Free Report)'s share price gapped up prior to trading on Friday. The stock had previously closed at $20.00, but opened at $21.00. Sensei Biotherapeutics shares last traded at $19.3890, with a volume of 10,288 shares trading hands. Wall Street Analysts Forecast Growth A number of equities analysts have recently
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways, today announced that Karen Vousden, Ph.D., has been appointed to its Board of Directors, effective September 11, 2026.“Karen helped shape the scientific thesis this company was built on, and she has been a trusted advisor to Faeth since its founding,” said Anand Parikh, Chairm…
Faeth Therapeutics, Inc. (Nasdaq: FTH), a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition o
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human can.
Does Faeth Therapeutics, Inc. (FTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
[url="]Faeth Therapeutics[/url] (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that management will participate in the following upcoming investor conferences:Wells Fargo 21st Annual Healthcare ConferenceTuesday, September 8, 20261x1 investor meetingsBoston, MACiti Biopharma Back to School SummitWednesday, September 9, 2026Fireside chat at 10:00 a.m. ETNew York, NYCantor G…
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted three new employees options to purchase an aggregate of 94,000 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted effective August 25, 2026, pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment.
The mean of analysts' price targets for Faeth Therapeutics, Inc. (FTH) points to a 72.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and.
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeth's technical operations organization, overseeing chemistry, manufacturing and controls (CMC), and supply chain activities supporting the company's PIKTOR clinical development progr.